Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.

Ma YL, Marin F, Stepan J, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Martínez G, Malouf J, Zeng QQ, Wan X, Recker RR

Bone22 Jan 2011Cited by 13 (Europe PMC)

PMID21262402DOI10.1016/j.bone.2011.01.012PepBankPUB-21262402

Publisher page PubMedAsk about this study

Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, combined periosteal MS/BS was greater with teriparatide than strontium ranelate.
In plain wordsIn women with osteoporosis, the combined periosteal mineralizing surface was greater with teriparatide than strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCombined periosteal mineralization surface
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Measurements
MS/BS
8.08%
teriparatide
MS/BS
3.22%
strontium ranelate
Source sentences
Summary
At the combined periosteal cortex, the mineralization surface as a percent of bone surface (MS/BS%) was greater for TPTD (mean±SE: 8.08±1.22%) than SrR (3.22±1.05%) (p<0.005).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240201
02HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, combined periosteal mineral apposition rate was significantly greater with teriparatide than strontium ranelate.
In plain wordsIn women with osteoporosis, periosteal mineral apposition was faster with teriparatide than strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCombined periosteal mineral apposition rate
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Measurements
MAR
0.35 μm/day
teriparatide
MAR
0.14 μm/day
strontium ranelate
Source sentences
Summary
The difference in mineral apposition rate (MAR) between TPTD (0.35±0.06μm/day) and SrR (0.14±0.06μm/day) was also significant (p<0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240202
03HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, combined periosteal bone formation rate did not differ significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, periosteal bone formation rate did not differ significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCombined periosteal bone formation rate
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Measurements
BFR/BS
0.014 mm(3)/mm(2)/year
teriparatide
BFR/BS
0.004 mm(3)/mm(2)/year
strontium ranelate
Source sentences
Summary
while that of bone formation rate per bone surface (BFR/BS) between TPTD (0.014±0.004 mm(3)/mm(2)/year) and SrR (0.004±0.003 mm(3)/mm(2)/year) was not (p=0.057).
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240203
04HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thicker periosteal cortex MS/BS differed significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thicker periosteal cortex mineralizing surface differed significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedThicker periosteal cortex MS/BS
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240204
05HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thicker periosteal cortex BFR/BS differed significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thicker periosteal cortex bone formation rate differed significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedThicker periosteal cortex BFR/BS
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240205
06HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thicker periosteal cortex MAR differed significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thicker periosteal cortex mineral apposition rate differed significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedThicker periosteal cortex MAR
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240206
07HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thicker periosteal cortex double-labeled perimeter differed significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thicker periosteal cortex double-labeled perimeter differed significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedThicker periosteal cortex double-labeled perimeter
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240207
08HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thinner periosteal cortex MS/BS did not differ significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thinner periosteal cortex mineralizing surface did not differ significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeThinner periosteal cortex MS/BS
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240208
09HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thinner periosteal cortex BFR/BS did not differ significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thinner periosteal cortex bone formation rate did not differ significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeThinner periosteal cortex BFR/BS
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240209
10HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thinner periosteal cortex MAR did not differ significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thinner periosteal cortex mineral apposition rate did not differ significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeThinner periosteal cortex MAR
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240210
11HumanNon-randomized trialEfficacy outcome
In women with osteoporosis, thinner periosteal cortex double-labeled perimeter did not differ significantly between teriparatide and strontium ranelate.
In plain wordsIn women with osteoporosis, thinner periosteal cortex double-labeled perimeter did not differ significantly between teriparatide and strontium ranelate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeThinner periosteal cortex double-labeled perimeter
Study
n = 49
Comparator
Strontium ranelate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20μg/day · subcutaneous · six monthsAs given in this study (human).
Source sentences
Summary
Statistically significant differences between the two treatments were also observed for MS/BS%, BFR/BS, MAR and the double-labeled perimeter in the periosteum of the thicker, but not thinner, iliac crest cortices.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
Report a problemFND-2126240211

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In teriparatide-treated women, periosteal MAR differed significantly between thicker and thinner cortices.
In plain wordsIn women receiving teriparatide, periosteal mineral apposition rate differed significantly between thicker and thinner cortices.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedPeriosteal MAR by cortex thickness
Study
n = 27
Comparator
Thinner versus thicker periosteal cortex
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The comparison between the thicker and thinner cortices of both periosteal and endosteal surfaces showed statistically significant differences for MAR and the double-labeled perimeter for TPTD treated women.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2126240212
13HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In teriparatide-treated women, endosteal MAR differed significantly between thicker and thinner cortices.
In plain wordsIn women receiving teriparatide, endosteal mineral apposition rate differed significantly between thicker and thinner cortices.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedEndosteal MAR by cortex thickness
Study
n = 27
Comparator
Thinner versus thicker endosteal cortex
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The comparison between the thicker and thinner cortices of both periosteal and endosteal surfaces showed statistically significant differences for MAR and the double-labeled perimeter for TPTD treated women.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2126240213
14HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In teriparatide-treated women, periosteal double-labeled perimeter differed significantly between thicker and thinner cortices.
In plain wordsIn women receiving teriparatide, periosteal double-labeled perimeter differed significantly between thicker and thinner cortices.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedPeriosteal double-labeled perimeter by cortex thickness
Study
n = 27
Comparator
Thinner versus thicker periosteal cortex
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The comparison between the thicker and thinner cortices of both periosteal and endosteal surfaces showed statistically significant differences for MAR and the double-labeled perimeter for TPTD treated women.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2126240214
15HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In teriparatide-treated women, endosteal double-labeled perimeter differed significantly between thicker and thinner cortices.
In plain wordsIn women receiving teriparatide, endosteal double-labeled perimeter differed significantly between thicker and thinner cortices.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedEndosteal double-labeled perimeter by cortex thickness
Study
n = 27
Comparator
Thinner versus thicker endosteal cortex
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The comparison between the thicker and thinner cortices of both periosteal and endosteal surfaces showed statistically significant differences for MAR and the double-labeled perimeter for TPTD treated women.
2 context sentences(design, population, supporting numbers)
Summary · context
We assessed the effects of subcutaneous injections of teriparatide (TPTD, 20μg/day) or oral strontium ranelate (SrR, 2g/day) in postmenopausal women with osteoporosis on new bone formation activity at the periosteal and endosteal bone surfaces using dynamic histomorphometric measurements.
Summary · context
Evaluable tetracycline-labeled transiliac crest bone biopsies were analyzed from 27 patients in the TPTD group, and 22 in the SrR group after six months of treatment.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2126240215

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.